Table 1 Characteristics of elderly patients with EOC in the training and validation groups
Characteristics | Total N (%) | Training group N (%) | Validation group N (%) | P |
|---|---|---|---|---|
Total | 5588 | 3724 | 1864 | |
Age at diagnosis (median, years) | 68(60–97) | 68(60–95) | 68(60–97) | 0.450 |
Year of diagnosis (years) | 0.380 | |||
2000–2006 | 1672 (29.9%) | 1117 (30.0%) | 555 (29.8%) | |
2007–2013 | 2802 (50.1%) | 1847 (49.6%) | 955 (51.2%) | |
2014–2019 | 1114 (19.9%) | 760 (20.4%) | 354 (19.0%) | |
Race | 0.077 | |||
White | 4940 (88.4%) | 3315 (89.0%) | 1625 (87.2%) | |
Black | 239 (4.3%) | 145 (3.9%) | 94 (5.0%) | |
Othera | 409 (7.3%) | 264 (7.1%) | 145 (7.8%) | |
Grade | 0.786 | |||
G1 | 431 (7.7%) | 284 (7.6%) | 147 (7.9%) | |
G2 | 1015 (18.2%) | 675 (18.1%) | 340 (18.2%) | |
G3 | 2635 (47.2%) | 1773 (47.6%) | 862 (46.2%) | |
G4 | 1507 (27.0%) | 992 (26.6%) | 515 (34.2%) | |
Histology | 0.003 | |||
Serous | 3825 (68.5%) | 2590 (69.5%) | 1235 (66.3%) | |
Mucinous | 276 (4.9%) | 168 (4.5%) | 108 (5.8%) | |
Endo/adeno | 900 (16.1%) | 584 (15.7%) | 316 (17.0%) | |
Clear cell | 392 (7.0%) | 270 (7.3%) | 122 (6.5%) | |
Otherb | 195 (3.5%) | 112 (3.0%) | 83 (4.5%) | |
AJCC Stage | 0.385 | |||
I | 1387 (24.8%) | 939 (25.2%) | 448 (24.0%) | |
II | 674 (12.1%) | 443 (11.9%) | 231 (12.4%) | |
III | 2597 (46.5%) | 1707 (45.8%) | 890 (47.7%) | |
IV | 930 (16.6%) | 635 (17.1%) | 295 (15.8%) | |
SEER Stage | 0.489 | |||
Local | 1205 (21.6%) | 819 (22.0%) | 386 (20.7%) | |
Regional | 790 (14.1%) | 518 (13.9%) | 272 (14.6%) | |
Distant | 3593 (64.3%) | 2387 (64.1%) | 1206 (64.7%) | |
CA-125 Pretreatment | 0.941 | |||
Negative | 305 (5.5%) | 206 (5.5%) | 99 (5.3%) | |
Positive | 2024 (36.2%) | 1349 (36.2%) | 675 (36.2%) | |
Unknown | 3529 (58.3%) | 2169 (58.2%) | 1090 (58.5%) | |
Laterality | 0.317 | |||
Unilateral | 3486 (62.4%) | 2317 (62.2%) | 1169 (62.7%) | |
Paired | 49 (0.9%) | 28 (0.8%) | 21 (1.1%) | |
Bilateral | 2053 (36.7%) | 1379 (37.0%) | 674 (36.2%) | |
T Stage | 0.223 | |||
T1 | 1290 (23.1%) | 868 (23.3%) | 422 (22.6%) | |
T2 | 748 (13.4%) | 499 (13.4%) | 249 (13.4%) | |
T3 | 2592 (46.4%) | 1746 (46.9%) | 846 (45.4%) | |
TX | 958 (17.1%) | 611 (16.4%) | 347 (18.6%) | |
Surgery | 0.920 | |||
Pelvic exenteration | 223 (4.0%) | 152 (4.1%) | 71 (3.8%) | |
Debulking | 2575 (46.1%) | 1721 (46.2%) | 854 (45.8%) | |
Local resection | 2774 (49.6%) | 1841 (49.4%) | 933 (50.1%) | |
No surgery | 16 (0.3%) | 10 (0.3%) | 6 (0.3%) | |
Lymph node examined (mean ± std) | 12.80 ± 12.119 | 12.96 ± 12.339 | 12.49 ± 11.664 | 0.192 |
Lymph node positive (mean ± std) | 1.810 ± 4.853 | 1.830 ± 4.888 | 1.760 ± 4.781 | 0.655 |
Radiation | 0.347 | |||
No /unknown | 5525 (98.9%) | 3678 (98.8%) | 1847 (99.1%) | |
Yes | 63 (1.1%) | 46 (1.2%) | 17 (0.9%) | |
Chemotherapy | 0.075 | |||
No /unknown | 1300 (23.3%) | 893 (24.0%) | 407 (21.8%) | |
Yes | 4288 (76.7%) | 2831 (76.0%) | 1457 (78.2%) | |
Bone metastasis | 0.675 | |||
No | 2804 (50.2%) | 1865 (50.1%) | 939 (50.4%) | |
Yes | 6 (0.1%) | 5 (0.1%) | 1 (0.1%) | |
Unknown | 2778 (49.7%) | 1854 (49.8%) | 924 (49.6%) | |
Lung metastasis | 0.981 | |||
No | 2728 (48.8%) | 1815 (48.7%) | 913 (49.0%) | |
Yes | 86 (1.5%) | 57 (1.5%) | 29 (1.6%) | |
Unknown | 2774 (49.6%) | 1852 (49.7%) | 922 (49.5%) | |
Liver metastasis | 0.995 | |||
No | 2715 (48.6%) | 1808 (48.5%) | 907 (48.7%) | |
Yes | 97 (1.7%) | 65 (1.7%) | 32 (1.7%) | |
Unknown | 2776 (49.7%) | 1851 (49.7%) | 925 (49.6%) | |
Brain metastasis | 0.467 | |||
No | 2806 (50.2%) | 1867 (50.1%) | 939 (50.4%) | |
Yes | 3 (0.1%) | 3 (0.1%) | 0(0.0%) | |
Unknown | 2779 (49.7%) | 1854 (49.8%) | 925 (49.6%) |